The company plans to manufacture for in-house dosage form production and for sales to other dosage form manufacturers.

When the company first submitted their application, the company submitted information to DEA that the firm would be manufacturing Oxymorphone for in-house dosage form production and sales to other dosage form manufacturers. Upon further investigation by the DEA it was uncovered that the company would only be producing bulk material for dosage form manufacturers. DEA will grant this registration for the production of bulk manufacturing of Oxymorphone.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Noramco Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Noramco Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance

Dated: June 7, 2007.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E7–11916 Filed 6–19–07; 8:45 am]
BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated February 5, 2007, and published in the **Federal Register** on February 12, 2007, (72 FR 6579), Orasure Technologies, Inc., Lehigh University, Seeley G. Mudd-Building 6, 220 East First Street, Bethlehem, Pennsylvania 18015, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II:

Drug	Schedule
Lysergic acid diethylamide (LSD) (7315).	I
4-Methoxyamphetamine (7411) Normorphine (9313)	1
Tetrahydrocannabinols (THC) (7370). Alphamethadol (9605)	
Amphetamine (1100)	II II
Cocaine (9041)	::
Benzoylecgonine (9180)	ii
Hydrocodone (9193) Morphine (9300)	II II
Oxycodone (9143) Meperidine (9230)	II II
Methadone (9250) Oxymorphone (9652)	II II

The company plans to manufacture the listed controlled substances in bulk to manufacture controlled substance derivatives. These derivatives will be used in diagnostic products created specifically for internal use only.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Orasure Technologies, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Orasure Technologies, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed.

Dated: June 7, 2007.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E7–11907 Filed 6–19–07; 8:45 am] BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importer of Controlled Substances; Notice of Registration

By Notice dated March 19, 2007 and published in the **Federal Register** on March 27, 2007, (72 FR 14297), Tocris Cookson, Inc., 16144 Westwoods Business Park, Ellisville, Missouri 63021–4500, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule I:

Drug	Schedule
Marihuana (7360) Tetrahydrocannabinols (7370)	

The company plans to import the above listed synthetic products for non-clinical laboratory based research only.

In reference to drug code 7360 (Marihuana), the company plans to import synthetic cannabidiol. In reference to drug code 7370 (Tetrahydrocannabinols), the company plans to import synthetic THC.

No other activity for this drug code is authorized for this registration.

No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Tocris Cookson, Inc. to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Tocris Cookson, Inc. to ensure that the company's registration is consistent with the public interest. The investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed.

Dated: June 7, 2007.

Joseph T. Rannazzisi,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. E7–11912 Filed 6–19–07; 8:45 am] **BILLING CODE 4410–09–P**

DEPARTMENT OF LABOR

Office of the Secretary

Submission for OMB Review: Comment Request

June 13, 2007.

The Department of Labor (DOL) has submitted the following public information collection request (ICR) to